ERBB2 and breast cancer: Notably, among 282 premenopausal Asian women with ER+ BC, those with HER2+ tumors may have received greater benefits, in terms of DFS and OS, from adjuvant oophorectomy and tamoxifen vs. no adjuvant therapy than those with HER2− BC [113].